Dr Paul Richardson speaks to ecancer about the ICARIA-MM final overall survival analysis. Isatuximab-irfc plus pomalidomide and low-dose dexamethasone (Isa-Pd) continues to show clinically meaningful benefit for patients with relapsed or refractory multiple myeloma demonstrating an improved overall survival (OS) over pomalidomide alone.

At a median follow-up of 35.3 months, the median OS was 24.6 months in the isatuximab group vs 17.7 months in the Pd group. Overall, there were 220 OS events with 106 in the Isa-Pd arm and 114 in the Pd arm.

Dr Richardson explains that the final analysis of this study also examined the impact of the Isa-PD treatment in the real world by observing deaths due to COVID-19.

These findings were presented at the 19th International Myeloma Society annual meeting, where researchers found that COVID-19 negatively impacted the overall survival of the Isa-Pd arm.

He concludes by talking about the clinical value of these results.